Price Alert

AstraZeneca (AZN)

NASDAQ: AZN · Real-Time Price · USD

85.59

0.28 (0.33%)

At close: Oct 06, 2025, 3:32 PM

0.33% (1D)

Bid	85.58
Market Cap	265.31B
Revenue (ttm)	56.5B
Net Income (ttm)	8.29B
EPS (ttm)	2.65
PE Ratio (ttm)	32.3
Forward PE	16.21
Analyst	n/a
Dividends	$2.05

Ask	85.59
Volume	5,225,569
Avg. Volume (20D)	4,632,300
Open	85.50
Previous Close	85.31
Day's Range	85.14 - 86.57
52-Week Range	61.24 - 86.57
Beta	0.17
Ex-Dividend Date	Aug 8, 2025

About AZN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AZN

Website n/a

Full Company Profile

Next Earnings Release

AstraZeneca is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 days ago

+9.96%

AstraZeneca shares are trading higher after the co... Unlock content with Pro Subscription

5 days ago

+3.49%

Shares of several drugmakers are trading higher after President Trump announced a deal with Pfizer as well as the 'TrumpRx' site to decrease prices.

News

8 hours ago · seekingalpha.com

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

1 hour ago · reuters.com

AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a dea...

1 hour ago · businesswire.com

Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca.

4 hours ago · reuters.com

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.

6 hours ago · reuters.com

AstraZeneca's Datroway boosts survival in advanced breast cancer trial

AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when gi...

3 days ago · zacks.com

Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Astrazeneca (AZN) closed at $85.31 in the latest trading session, marking a +1.98% move from the prior day.

3 days ago · seekingalpha.com

Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated

Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...

3 days ago · fool.com

AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?

Shares of AstraZeneca (AZN -0.84%) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early brea...